TSE:VBV - VBI Vaccines Stock Price, Price Target & More

C$4.82 -0.26 (-5.12 %)
(As of 04/20/2018 04:00 PM ET)
Previous CloseC$4.82
Today's RangeC$4.82 - C$5.05
52-Week RangeC$3.85 - C$7.60
Volume1,300 shs
Average Volume3,637 shs
Market CapitalizationC$253.84 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65

About VBI Vaccines (TSE:VBV)

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Receive VBV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:VBV
CUSIPN/A
Phone+1-617-8303031

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-5,078.76%
Return on Equity-59.42%
Return on Assets-43.57%

Miscellaneous

EmployeesN/A
Outstanding Shares64,079,000

How to Become a New Pot Stock Millionaire

VBI Vaccines (TSE:VBV) Frequently Asked Questions

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VBV."

Who are some of VBI Vaccines' key competitors?

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the folowing people:
  • Mr. Jeff R. Baxter, CEO, Pres & Director (Age 57)
  • Dr. David Evander Anderson Ph.D., Chief Scientific Officer (Age 48)
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Principal Financial & Accounting Officer, Chief Compliance Officer (Age 53)
  • Ms. Nell Beattie, Chief Bus. Officer (Age 30)
  • Dr. Francisco Diaz-Mitoma M.D., Ph.D., Chief Medical Officer (Age 63)

Has VBI Vaccines been receiving favorable news coverage?

Media coverage about VBV stock has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. VBI Vaccines earned a media sentiment score of 0.14 on Accern's scale. They also gave news stories about the company an impact score of 45.98 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of VBI Vaccines?

Shares of VBV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is VBI Vaccines' stock price today?

One share of VBV stock can currently be purchased for approximately C$4.82.

How big of a company is VBI Vaccines?

VBI Vaccines has a market capitalization of C$253.84 million.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 3rd St Ste 2241, CAMBRIDGE, MA 02142-1259, United States. The company can be reached via phone at +1-617-8303031.


MarketBeat Community Rating for VBI Vaccines (VBV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  16 (Vote Underperform)
Total Votes:  38
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

VBI Vaccines (TSE:VBV) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/21/2016 forward)

Earnings

VBI Vaccines (TSE:VBV) Earnings History and Estimates Chart

Earnings by Quarter for VBI Vaccines (TSE:VBV)

VBI Vaccines (TSE VBV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017C($0.29)C($0.30)C$0.19 millionC$0.24 millionViewN/AView Earnings Details
7/31/2017Q2 2017C($0.28)C($0.30)C$0.18 millionC$0.46 millionViewN/AView Earnings Details
3/24/2017Q4 2016C($0.24)C$0.14 millionViewN/AView Earnings Details
8/15/2016Q2 2016C($0.30)C$0.11 millionViewN/AView Earnings Details
11/16/2015Q3 2015C($0.40)C$0.14 millionViewN/AView Earnings Details
8/14/2015Q2 2015C($0.40)ViewN/AView Earnings Details
2/6/2015Q4 2014C($0.40)ViewN/AView Earnings Details
8/12/2014Q2 2014C($0.40)ViewN/AView Earnings Details
6/25/2014Q1 2014C($1.20)ViewN/AView Earnings Details
2/13/2014Q4 2013C($0.40)ViewN/AView Earnings Details
11/13/2013Q3 2013C($0.40)ViewN/AView Earnings Details
2/12/2013Q4 2012C($0.40)ViewN/AView Earnings Details
11/13/2012Q3 2012C($0.68)ViewN/AView Earnings Details
8/15/2012Q2 2012C($0.36)ViewN/AView Earnings Details
6/29/2012Q1 2012C($0.80)ViewN/AView Earnings Details
3/26/2012Q1 2010C($0.40)ViewN/AView Earnings Details
2/29/2012Q4 2011C($0.56)ViewN/AView Earnings Details
11/30/2011Q3 2011C($0.68)ViewN/AView Earnings Details
9/28/2011Q2 2011C($0.88)ViewN/AView Earnings Details
7/28/2011Q1 2011C($5.48)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

VBI Vaccines (TSE:VBV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

VBI Vaccines (TSE VBV) Insider Trading and Institutional Ownership History

Insider Trading History for VBI Vaccines (TSE:VBV)

VBI Vaccines (TSE VBV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2017Jeffrey Royston BaxterDirectorBuy4,609C$3.88C$17,882.92
11/28/2017Jeffrey Royston BaxterDirectorBuy15,000C$4.75C$71,250.00
8/21/2017Francisco Diaz-MitomaInsiderBuy3,000C$3.17C$9,510.00
8/21/2017Jeffrey Royston BaxterDirectorBuy10,000C$3.22C$32,200.00
(Data available from 1/1/2013 forward)

Headlines

VBI Vaccines (TSE VBV) News Headlines

Source:

SEC Filings

VBI Vaccines (TSE:VBV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

VBI Vaccines (TSE VBV) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.